Jupiter Neurosciences, Inc. is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer market with its Nugevia product line. The Company's pharmaceutical product pipeline is built around its proprietary platform product, JOTROL, an enhanced oral formulation of resveratrol. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Its segments include premium nutritional supplements, and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. The Company's Nugevia product line supplements space, supporting mental clarity, skin health, and mitochondrial function. It is also focused on a Phase IIa clinical study in Parkinson's disease. It also has rights in ALA-002.
Back to dashboard
Company Information
About this company
Key people
Christer Rosen
Chairman of the Board, Chief Executive Officer, Co-Founder
Alison D. Silva
President, Chief Operating Officer, Director
Alexander Gustaf Erik Rosen
Co-Founder, Chief Administrative Officer
Marshall A. Hayward
Co-Founder, Chief Scientific Officer, Director
Saleem Elmasri
Chief Financial Officer
Tomas J. Philipson
Director
Nicholas H. Hemmerly
Independent Director
Julie Kampf
Independent Director
Holger Weis
Independent Director
Click to see more
Key facts
- Shares in issue1.32m
- EPICJUNS
- ISINUS48208B3024
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$3.77m
- Employees5
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.